Glycopyrrolate Injection shortage
Glycopyrrolate Injection is currently listed in shortage by the FDA. The FDA lists 4 affected products. This page was last refreshed from FDA data on Sep 22, 2026.
Fresenius Kabi is permanently stopping production of glycopyrrolate injection. Other makers — including Hikma, American Regent, Sandoz, and Accord — still list glycopyrrolate injection in their supply, so the medicine may be available from other sources.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Glycopyrrolate Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jul 30, 2026Currently in shortage4 of 4 products affected.
-
Jul 30, 2026First reported to the FDA4 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Glycopyrrolate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Glycopyrrolate Injection? options further down this page.
Why is Glycopyrrolate Injection in shortage?
Fresenius Kabi USA has decided to permanently stop making their versions of Glycopyrrolate Injection. This affects all three strengths and package sizes they produced: the 0.2 mg/1 mL vial, the 0.4 mg/2 mL vial, and the 1 mg/5 mL vial. They haven't shared a specific public reason for why they made this decision — just that they are discontinuing manufacturing of these products entirely.
It's worth knowing that this report only covers Fresenius Kabi's products specifically. Other manufacturers of Glycopyrrolate Injection may be listed separately on this page and are not part of this particular discontinuation notice.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Glycopyrrolate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Glycopyrrolate Injection?
Glycopyrrolate Injection is currently listed on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The manufacturer that filed this report, Fresenius Kabi USA, is discontinuing all of its listed strengths: 0.2 mg/1 mL, 0.4 mg per 2 mL, and 1 mg per 5 mL. None of these currently have an available source from that maker, and the reason given is that they are ending production. Because this is a discontinuation rather than a temporary delay, this particular supply may be permanent. That said, this report reflects only one manufacturer — other companies still make the same medicine, so it is not gone from the market entirely.
Please do not stop, skip, or change your doses on your own. Here is how to move forward:
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine (same ingredient, form, and route) is listed as available from makers such as Hikma, American Regent, Sandoz, Accord, Sagent, and others, though it may not be in local stock right away.
- If your exact strength cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match local stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Where else can I get Glycopyrrolate Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Glycopyrrolate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9584-10 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection, Solution · Intramuscular, Intravenous | American Regent, Inc. | 00517-4601-25 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection · Intramuscular, Intravenous | Sandoz Inc | 00781-3825-96 |
| Glycopyrrolate | GLYCOPYRROLATE .4 mg/2mL | Injection · Intramuscular, Intravenous | Sandoz Inc | 00781-3827-96 |
| Glycopyrrolate | GLYCOPYRROLATE 1 mg/5mL | Injection · Intramuscular, Intravenous | Sandoz Inc | 00781-3829-96 |
| Glycopyrrolate | GLYCOPYRROLATE 4 mg/20mL | Injection · Intramuscular, Intravenous | Sandoz Inc | 00781-3831-95 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection · Intramuscular, Intravenous | Accord Healthcare, Inc., | 16729-0471-08 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection, Solution · Intramuscular, Intravenous | Sagent Pharmaceuticals | 25021-0796-01 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection · Intramuscular, Intravenous | Solco Healthcare US, LLC | 43547-0543-25 |
| Glycopyrrolate | GLYCOPYRROLATE .4 mg/2mL | Injection · Intramuscular, Intravenous | Solco Healthcare US, LLC | 43547-0544-25 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection, Solution · Intramuscular, Intravenous | AuroMedics Pharma LLC | 55150-0292-01 |
| Glycopyrrolate | GLYCOPYRROLATE .2 mg/mL | Injection · Intramuscular, Intravenous | Alembic Pharmaceuticals Inc. | 62332-0607-25 |
Alternative dosage forms of Glycopyrrolate
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Glycopyrrolate .2 mg/mL | Hikma | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | American | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Sandoz | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Sagent | 10 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Solco | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Solco | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Alembic | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Fresenius | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Caplin | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Fresenius | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Piramal | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Somerset | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Somerset | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Xiromed | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Meitheal | 25 vials | $1.481 | AP | Availability likely |
| glycopyrrolate .2 mg/mL | BE | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Civica, | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Civica, | 25 vials | $1.481 | AP | Availability likely |
| Glycopyrrolate .2 mg/mL | Hikma | 25 vials | — | AP | FDA listed |
| Glycopyrrolate .2 mg/mL | Henry | 1 vial | — | AP | FDA listed |
| Glycopyrrolate .2 mg/mL | Henry | 1 vial | — | AP | Discontinued |
| Glycopyrrolate .2 mg/mL | Accord | 25 vials | — | AP | FDA listed |
| Glycopyrrolate .2 mg/mL | HF | 1 ml | — | AP | FDA listed |
| Glycopyrrolate .2 mg/mL | HF | 1 ml | — | AP | FDA listed |
| Glyrx-Pf .2 mg/mL | Exela | 25 vials | — | — | FDA listed |
| Glycopyrrolate .2 mg/mL | AuroMedics | 25 vials | — | — | FDA listed |
| Glycopyrrolate .2 mg/mL | Cardinal | 5 vials | — | AP | FDA listed |
| Glycopyrrolate .2 mg/mL | Gland | 25 vials | — | AP | FDA listed |
| Glycopyrrolate .2 mg/mL | Amneal | 25 vials | — | AP | FDA listed |
| Glycopyrrolate 1Ml .2 mg/mL | XIROMED | 1 vial | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Glycopyrrolate Injection — that fall in the same broad treatment class (anticholinergics,quaternary ammonium) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anesthesia shortages
Glycopyrrolate Injection shortage FAQs
Is Glycopyrrolate Injection in shortage?
Which products are affected?
When will Glycopyrrolate Injection be available again?
Can I still get Glycopyrrolate somewhere?
What should I do if I take Glycopyrrolate Injection?
Still have a question about the Glycopyrrolate Injection shortage?
Ask a pharmacist about this shortage →View Glycopyrrolate Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.